Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-22 07:49 CEST (UTC+2h)

FDA Study Population Requirement for BE Studies: Ethics or Science [Regulatives / Guidelines]

posted by jag009 - NJ, 2018-05-18 16:28  - Posting: # 18785
Views: 332

Hi,

» For IND and NDAs, I can understand the need for representative population. But for ANDA submissions for the registration of generics, I wonder why there is need for the use of representative population. Is it based on the need for equity (ethics) or for soundness of data (science)?

Personally I don't see this "representative population" is enforced since many ANDA (and NDA to a certain extent) studies now being conducted in India (as an example) and the study population is basically Indians. In addition, take Indian studies for example, it's very difficult (if not impossible) to get 50-50 or even 40-60 female to male ratios in a study. I have conducted studies India as well and my M/F ratios are usually 80-20 or 90-10 (sometime no females!).

I believe it's a good idea for the study population to be diverse.

John

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,192 registered users;
online 14 (1 registered, 13 guests [including 11 identified bots]).

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed